DrugPatentWatch Database Preview
Drugs in Development Information for Danirixin
» See Plans and Pricing
What is the drug development status for Danirixin?
Danirixin is an investigational drug.
There have been 10 clinical trials for Danirixin.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 28th 2017.
The most common disease conditions in clinical trials are Lung Diseases, Chronic Disease, and Pulmonary Disease, Chronic Obstructive. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].
There are twenty-five US patents protecting this investigational drug and two hundred and eighty-nine international patents.
Summary for Danirixin
| US Patents | 25 |
| International Patents | 289 |
| US Patent Applications | 87 |
| WIPO Patent Applications | 65 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 2 (2017-04-28) |
| Vendors | 22 |
Recent Clinical Trials for Danirixin
| Title | Sponsor | Phase |
|---|---|---|
| GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects | GlaxoSmithKline | Phase 1 |
| Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD) | GlaxoSmithKline | Phase 2 |
| A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) | GlaxoSmithKline | Phase 2 |
Clinical Trial Summary for Danirixin
Top disease conditions for Danirixin
Top clinical trial sponsors for Danirixin
US Patents for Danirixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Danirixin | Start Trial | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | Start Trial |
| Danirixin | Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Start Trial |
| Danirixin | Start Trial | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | Pfizer Inc. (New York, NY) | Start Trial |
| Danirixin | Start Trial | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| Danirixin | Start Trial | Fused imidazo-piperidine JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| Danirixin | Start Trial | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | Start Trial |
| Danirixin | Start Trial | Therapeutic compounds and compositions, and methods of use thereof | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Danirixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Danirixin | Australia | AU2013227351 | 2032-02-28 | Start Trial |
| Danirixin | Australia | AU2016202881 | 2032-02-28 | Start Trial |
| Danirixin | Australia | AU2017213466 | 2032-02-28 | Start Trial |
| Danirixin | Canada | CA2865702 | 2032-02-28 | Start Trial |
| Danirixin | China | CN104703584 | 2032-02-28 | Start Trial |
| Danirixin | China | CN107875127 | 2032-02-28 | Start Trial |
| Danirixin | European Patent Office | EP2819645 | 2032-02-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
